Explain this page
Arphra AIPlain-English read on BeOne Medicines Ltd.’s valuation06-11today
- BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit9d
- BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit9d
- BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?15d
- BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma38d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $399.11 (+47.74%)
Candlestick · 1Y
Open in chart workstation →ONC
270.15+9.34%H 385.22L 239.25MA50 295.53MA200 318.35Avg vol 291K
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.84% | +1.92% | -12.50% | -1.86% | -14.52% | -11.08% | +9.34% | +41.02% | -17.04% | +801.40% | +853.92% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$270.15
49 sh
Bid
$250.00
1 sh
Ask
$274.00
10 sh
Spread
$24.000
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefitbusinesswire.com·Jun 11, 2026
- BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefitbusinesswire.com·Jun 11, 2026
- BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?zacks.com·Jun 05, 2026
- BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphomabusinesswire.com·May 13, 2026
- BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphomabusinesswire.com·May 13, 2026
- BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updatesbusinesswire.com·May 06, 2026
Recent analyst activity
DB- Jun 02, 2026GradeOutperform → OutperformBeOne Medicines (ONC) PT Raised to $436 at RBC CapitalRBC Capital
- Jun 02, 2026PT$436.00BeOne Medicines (ONC) PT Raised to $436 at RBC CapitalRBC Capital
Peers
No peer list available for ONC.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|